FindTrial
Sign In

A study of fake and duplicate Drugs: Challenges in the global market

Substandard, Spurious, Falsely Labelled, Falsified and Counterfeit Drugs in Global Regulatory System: Challenges and Regulatory Approaches - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/10/096110
Enrollment
482
Registered
2025-10-15
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Shailee Dewan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Registered Raw materials vendor, experienced QA/QC industry personnel, Regulatory authorities, Registered Wholesaler/ Distributor and Retailer shall be included in this study.

Exclusion criteria

Exclusion criteria: Unlicensed vendors, fresher or inexperienced industry personnel and unregistered dealers to be excluded.

Design outcomes

Primary

MeasureTime frame
By examining the knowledge, attitude and practices of the stakeholders and the industry experts, Indian supply chain management shall be mapped in detail for the study of SSFFC drugsTimepoint: For pilot study 8 weeks, then main study further for 48 weeks—

Secondary

MeasureTime frame
By examining the perspective of the stakeholders & the industry experts, Regulatory model can be developed in Indian context for SSFFC drugsTimepoint: After 48 weeks of KAP study.—

Countries

India

Contacts

Public ContactD r Pradeep M Muragundi

Manipal College of Pharmaceutical Sciences

pradeep.mm@manipal.edu0822922482

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026